Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial

被引：11
|
作者：
Sternberg, Cora N.
De Bono, Johann Sebastian
Chi, Kim N.
Fizazi, Karim
Mulders, Peter
Hirmand, Mohammad
Forer, David
Scher, Howard I.
机构：
[1] San Camillo & Forlanini Hosp, Rome, Italy
[2] Inst Canc Res, Sutton, Surrey, England
[3] British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC V5Z 4E6, Canada
[4] Univ Paris 11, Inst Gustave Roussy, Villejuif, France
[5] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands
[6] Medivation Inc, San Francisco, CA USA
[7] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer
    Banna, Giuseppe L.
    Urzia, Valeria
    Benanti, Chiara
    Pitre, Alessandra
    Lipari, Helga
    Di Quattro, Rosario
    De Giorgi, Ugo
    Schepisi, Giuseppe
    Basso, Umberto
    Bimbatti, Davide
    Rundo, Francesco
    Libra, Massimo
    Malatino, Lorenzo
    SUPPORTIVE CARE IN CANCER, 2020, 28 (10) : 4687 - 4695
  • [22] Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer
    Giuseppe L. Banna
    Valeria Urzia
    Chiara Benanti
    Alessandra Pitrè
    Helga Lipari
    Rosario Di Quattro
    Ugo De Giorgi
    Giuseppe Schepisi
    Umberto Basso
    Davide Bimbatti
    Francesco Rundo
    Massimo Libra
    Lorenzo Malatino
    Supportive Care in Cancer, 2020, 28 : 4687 - 4695
  • [23] Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study).
    Fleisher, Martin
    Danila, Daniel Costin
    Fizazi, Karim
    Hirmand, Mohammad
    Selby, Brian
    Phung, De
    De Bono, Johann Sebastian
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
    La, Jennifer
    Wang, Lin
    Corrigan, June K.
    Lang, Deborah
    Lee, Michelle H.
    Do, Nhan V.
    Brophy, Mary T.
    Paller, Channing J.
    Fillmore, Nathanael R.
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [25] Optimal sequencing of enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC)
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa Maria
    Bassi, Sunakshi
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [26] KEYNOTE-641: Phase III study of pembrolizumab (pembro) plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC)
    Graff, J. N.
    Burgents, J.
    Liang, L. W.
    Stenzl, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] Phase II study of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) and progression on enzalutamide (enza).
    Teply, Benjamin A.
    Wang, Hao
    Sullivan, Rana
    Rifkind, Irina
    Bruns, Ashley
    Decarli, Morgan
    Sinibaldi, Victoria J.
    Pratz, Caroline F.
    Luo, Jun
    Carducci, Michael Anthony
    Paller, Channing Judith
    Antonarakis, Emmanuel S.
    Eisenberger, Mario A.
    Denmeade, Samuel R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
    Schalken, Jack
    Fitzpatrick, John M.
    BJU INTERNATIONAL, 2016, 117 (02) : 215 - 225
  • [29] Clinical outcomes and safety in men ≥ 75 and < 75 years with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in the phase 3 PREVAIL trial.
    Graff, Julie Nicole
    Baciarello, Giulia
    Armstrong, Andrew J.
    Higano, Celestia S.
    Iversen, Peter
    Forer, David
    Mansbach, Harry H.
    Phung, De
    Tombal, Bertrand F.
    Beer, Tomasz M.
    Sternberg, Cora N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [30] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Rana, Dikshyanta
    Geue, Claudia
    Baillie, Kelly
    Pan, Jiafeng
    Mueller, Tanja
    Laskey, Jennifer
    Bennie, Marion
    Clarke, Julie
    Jones, Robert J.
    Brown, Ailsa
    Wu, Olivia
    PHARMACOECONOMICS-OPEN, 2022, 6 (02) : 303 - 313
12345